This Article Full Text Full Text (PDF) Correction (v13,p5226) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sterman, D. H. Articles by Albelda, S. M. Search for Related Content PubMed PubMed Citation Articles by Sterman, D. H. Articles by Albelda, S. M.

A Phase I Clinical Trial of Single-Dose Intrapleural IFN-ß Gene Transfer for Malignant Pleural Mesothelioma and Metastatic Pleural Effusions: High Rate of Antitumor Immune Responses

Authors' Affiliations: ¹ Thoracic Oncology Gene Therapy Program and ² Abramson Family Cancer Research Institute, University of Pennsylvania Medical Center; ³ Virology Laboratory, Children's Hospital of Philadelphia; ⁴ Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania; ⁵ BiogenIdec, Cambridge, Massachusetts; ⁶ Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland; and ⁷ Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Daniel H. Sterman, Interventional Pulmonology Program, Pulmonary, Allergy and Critical Care Division, University of Pennsylvania Medical Center, 833 West Gates Building, 3400 Spruce Street, Philadelphia, PA 19104-4283. Phone: 215-614-0984; Fax: 215-662-3226; E-mail: sterman{at}mail.med.upenn.edu.

Purpose: This phase 1 dose escalation study evaluated the safety and feasibility of single-dose intrapleural IFN-ß gene transfer using an adenoviral vector (Ad.IFN-ß) in patients with malignant pleural mesothelioma (MPM) and metastatic pleural effusions (MPE).

Experimental Design: Ad.IFN-ß was administered through an indwelling pleural catheter in doses ranging from 9 x 10¹¹ to 3 x 10¹² viral particles (vp) in two cohorts of patients with MPM (7 patients) and MPE (3 patients). Subjects were evaluated for (a) toxicity, (b) gene transfer, (c) humoral, cellular, and cytokine-mediated immune responses, and (d) tumor responses via 18-fluorodeoxyglucose-positron emission tomography scans and chest computed tomography scans.

Results: Intrapleural Ad.IFN-ß was generally well tolerated with transient lymphopenia as the most common side effect. The maximally tolerated dose achieved was 9 x 10¹¹ vp secondary to idiosyncratic dose-limiting toxicities (hypoxia and liver function abnormalities) in two patients treated at 3 x 10¹² vp. The presence of the vector did not elicit a marked cellular infiltrate in the pleural space. Intrapleural levels of cytokines were highly variable at baseline and after response to gene transfer. Gene transfer was documented in 7 of the 10 patients by demonstration of IFN-ß message or protein. Antitumor immune responses were elicited in 7 of the 10 patients and included the detection of cytotoxic T cells (1 patient), activation of circulating natural killer cells (2 patients), and humoral responses to known (Simian virus 40 large T antigen and mesothelin) and unknown tumor antigens (7 patients). Four of 10 patients showed meaningful clinical responses defined as disease stability and/or regression on 18-fluorodeoxyglucose-positron emission tomography and computed tomography scans at day 60 after vector infusion.

Conclusions: Intrapleural instillation of Ad.IFN-ß is a potentially useful approach for the generation of antitumor immune responses in MPM and MPE patients and should be investigated further for overall clinical efficacy.

This article has been cited by other articles:

				C. Jackaman, S. Cornwall, A. M. Lew, Y. Zhan, B. W. S. Robinson, and D. J. Nelson Local effector failure in mesothelioma is not mediated by CD4+ CD25+ T-regulator cells Eur. Respir. J., July 1, 2009; 34(1): 162 - 175. [Abstract] [Full Text] [PDF]

				B. D. Grigoriu, B. Chahine, A. Vachani, T. Gey, M. Conti, D. H. Sterman, G. Marchandise, H. Porte, S. M. Albelda, and A. Scherpereel Kinetics of Soluble Mesothelin in Patients with Malignant Pleural Mesothelioma during Treatment Am. J. Respir. Crit. Care Med., May 15, 2009; 179(10): 950 - 954. [Abstract] [Full Text] [PDF]

				A. S. Tsao, I. Wistuba, J. A. Roth, and H. L. Kindler Malignant Pleural Mesothelioma J. Clin. Oncol., April 20, 2009; 27(12): 2081 - 2090. [Abstract] [Full Text] [PDF]

				O. Kaneko, L. Gong, J. Zhang, J. K. Hansen, R. Hassan, B. Lee, and M. Ho A Binding Domain on Mesothelin for CA125/MUC16 J. Biol. Chem., February 6, 2009; 284(6): 3739 - 3749. [Abstract] [Full Text] [PDF]

				S. Kim, G. Buchlis, Z. G. Fridlender, J. Sun, V. Kapoor, G. Cheng, A. Haas, H. K. Cheung, X. Zhang, M. Corbley, et al. Systemic Blockade of Transforming Growth Factor-{beta} Signaling Augments the Efficacy of Immunogene Therapy Cancer Res., December 15, 2008; 68(24): 10247 - 10256. [Abstract] [Full Text] [PDF]

				A. Gauvrit, S. Brandler, C. Sapede-Peroz, N. Boisgerault, F. Tangy, and M. Gregoire Measles Virus Induces Oncolysis of Mesothelioma Cells and Allows Dendritic Cells to Cross-Prime Tumor-Specific CD8 Response Cancer Res., June 15, 2008; 68(12): 4882 - 4892. [Abstract] [Full Text] [PDF]